Friedrich-Schiller-Universitaet Jena

8 trials 3 recruiting Academic / non-commercial Merged from 2 name variants

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

3 Recruiting

6 Completed trials

2 Countries active

18 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 4 Phase II: 4

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic myeloid leukaemia 2 Prostate cancer metastatic 1 Hormone-dependent prostate cancer 1 Encephalitis autoimmune 1

Top IMPs

ALLOGENEIC FAECAL MICROBIOTA, POOLED 1 BUSERELIN ACETATE 1 DAROLUTAMIDE 1 DEGARELIX 1 DOCETAXEL 1 EMPAGLIFLOZIN 1 EPIRUBICIN HYDROCHLORIDE 1 GOSERELIN ACETATE 1 LEUPRORELIN ACETATE 1 RELUGOLIX 1 SODIUM CHLORIDE 1

All trials

8 total

Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute d… Recruiting

2024-517977-26-00 Phase III 1 country EMPAGLIFLOZIN
Effect of acyclovir therapy on the outcome of ventilated patients with lower respiratory tract infection and detection of herpes simplex vir… Recruiting

2023-504322-19-00 Phase III 1 country
A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune … Recruiting

2024-514494-21-00 Phase II 1 country
Frontline Asciminib combination in chronic phase CML Ended

2024-516212-24-00 Phase II 1 country
A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended

2022-502634-52-00 Phase III 2 countries BUSERELIN ACETATE; DAROLUTAMIDE; DEGARELIX; DOCETAXEL; GOSERELIN ACETATE; LEUPRO…
Multicenter, prospective, double-blind, randomized, three-armed, placebo-controlled study of long-term therapeutic transfer of encapsulated … Ended

2024-517132-22-00 Phase III 1 country ALLOGENEIC FAECAL MICROBIOTA, POOLED
Venetoclax after TKI to target persisting stem cells in CML Ended

2024-516214-38-00 Phase II 1 country
Epirubicin for the Treatment of Sepsis & Septic Shock Ended

2024-515776-12-00 Phase II 1 country EPIRUBICIN HYDROCHLORIDE; SODIUM CHLORIDE

Showing 1–8 of 8 trials

← All sponsors A–Z